Clinical Trials on HPV - Anogenital Human Papilloma Virus Infection in Austria

Total 764 results

Kirby Institute
National Health and Medical Research Council, Australia

Recruiting

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS II)

Hepatitis C

Australia
ViiV Healthcare

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

HIV Infections

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Hepatitis A

United States
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

HIV Infections

United States
AiCuris Anti-infective Cures AG
Medpace, Inc.

Recruiting

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

HSV Infection

United States, Italy, Belgium, France, United Kingdom, Germany, Switzerland, Argentina, Australia, Georgia, Greece, Mexico, Israel, Canada
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Completed

The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital

Hepatitis C

Australia, New Zealand
Kirby Institute

Recruiting

Real World Assessment of People Living With Chronic Hepatitis B in Australia (REACH-B)

Hepatitis B

Australia
Macfarlane Burnet Institute for Medical Research...
National Health and Medical Research Council, Australia; Gilead Sciences; The... and other collaborators

Recruiting

Eliminate Hepatitis C/EC Partnership Evaluation Protocol

Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis c

Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

Hepatitis C, Chronic

Austria
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
GlaxoSmithKline

Completed

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

Virus Diseases

United States, South Africa, Australia
ViiV Healthcare

Recruiting

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

HIV Infections

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

HIV Infections | Peripheral Neuropathy

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
DiaSorin Molecular LLC

Completed

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

Coronavirus Disease 2019 | Influenza A | Influenza Type B

Australia
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
GlaxoSmithKline

Completed

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

Influenza

United States
Romark Laboratories L.C.

Completed

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Influenza

United States, Australia, Puerto Rico
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
Response Biomedical Corp.

Completed

FLU A+B Nasal Swab Clinical Study (FLUA+B)

Influenza

United States, Canada
Hoffmann-La Roche

Completed

Influenza Resistance Information Study (IRIS)

Influenza

Australia, Hong Kong, United States, France, Germany, Netherlands, Norway, Poland
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Pfizer

Completed

Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

Human Immunodeficiency Virus

United States, Spain, South Africa, Italy, France, Germany
Medicago

Completed

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza

United States, Canada, Finland, Germany, Philippines, Thailand, United Kingdom
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
Bristol-Myers Squibb

Completed

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Hepatitis C Virus

Australia, United States, Canada, France, Denmark, Italy
Assembly Biosciences

Completed

Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Taiwan, Australia, Hong Kong, United Kingdom
St Vincent's Hospital Melbourne
Merck Sharp & Dohme LLC

Unknown

A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6)

Chronic Hepatitis C

Australia
Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
Kirby Institute
AbbVie

Completed

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D)

Hepatitis C, Acute

United Kingdom, Australia, New Zealand
Kirby Institute
Flinders University

Recruiting

The National Australian HCV Point-of-Care Testing Program

Hepatitis C

Australia
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Influenza

United States, Canada
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)

Hepatitis C

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
HepNet Study House, German Liverfoundation
Hannover Medical School; German Center for Infection Research

Completed

The Hepatitis Delta International Network (HDIN)

Hepatitis D

Germany, Austria, Belgium, Brazil, Georgia, Greece, Italy, Moldova, Republic of, Pakistan, Romania, Spain, Vietnam
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

HIV Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States
Gilead Sciences

Completed

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Hepatitis C

United States, Canada, United Kingdom, Australia, New Zealand
Tibotec Pharmaceuticals, Ireland

Completed

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

HIV Infection

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Portugal, Canada, Argentina, Brazil, Austria, Hungary
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Romark Laboratories L.C.

Completed

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

Influenza

United States, Australia, Puerto Rico
Dynavax Technologies Corporation

Completed

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Hepatitis B

United States
Abbott Biologicals
Quintiles, Inc.

Completed

Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine

Influenza

Australia, New Zealand
Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands

3

Subscribe